Changes to OTC cannabis sales just around the corner

By Jonathan Jackson. Published at Nov 26, 2020, in ASX Biotechs

The Therapeutic Goods Administration (TGA) will shortly bring down its final decision regarding a major regulatory change in the distribution of cannabidiol (CBD) products in Australia.

The final decision is expected to be delivered in late December 2020, following on from the interim decision made in September.

The changes recommend that CBD products be down scheduled from schedule 4 and classified as schedule 3 medicines in Australia, which would allow Australian consumers to purchase CBD products over-the-counter (OTC) through pharmacies without the requirement of a prescription.

Read: Creso Pharma to benefit from OTC cannabis sales in Australia

It has been a slow but welcome move to get to this point. It wasn’t until 2016 that Australia legally recognised the difference between marijuana and hemp. Before that , cannabis products were classified as Schedule (S8) Drugs and were strictly regulated and deemed poisonous.

Following that, the TGA lifted the ban on hemp extracts.

It did so under the Australian medical cannabis program, with the downregulation leading to CBD oil being knocked down to a Schedule 4 (S4) classification.

With this new legislature, December’s changes will be welcome but strict.

CBD content must be at 98% or less, with the remaining 2% allowed to be any of the other 100+ phytocannabinoids found in hemp.

The TGA’s cautious approach is due to its belief that there are too few studies on each individual phytocannabinoid other than CBD and THC to deem these others safe or effective for medical treatment.

However, the decision regarding amendments to down schedule cannabidiol (CBD) products to schedule 3 medicine would allow Australian consumers to purchase CBD products following consultation with a pharmacist without the need for a prescription.

This is a major move forward.

Once the announcement is made official, a doctor when writing a prescription will be required to fill out a Special Access Scheme (SAS) – an official petition to the TGA to allow patients to access CBD oil under the Australian medical cannabis program.

At the moment, doctors can only prescribe approved items by the Australian Register of Therapeutic Goods (ARTG).

Creso Pharma ready to help make a difference

For Creso Pharma (ASX:CPH), the potential down scheduling of CBD products in Australia could unlock a major market for its CBD and hemp products.

It is estimated that the local market is currently at over $200M per annum and growing.

CPH develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

It uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It also has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

“The potential down scheduling of CBD is a major development for the broader market and provides Creso Pharma with a number of opportunities and potential new sales channels,” Non-Executive Chairman Adam Blumenthal said.

“Australia has always been considered an important market in our growth strategy. Ahead of the TGA’s final decision, the Board and management have been exploring initiatives which will allow us to capture a large market share in Australia and unlock value for our shareholders.

“The Company remains well capitalised and looks forward to providing ongoing updates on progress.”

CPH already has products available on the Australianb market.

Its cannaQIX® 50 is currently being sold in Australia as a medicinal cannabis product under the ‘LozaCan’ brand via distribution partner ‘Burleigh Heads Cannabis’ (BHC).

Creso has also developed a wide range of CBD and hemp-oil products under the cannaQIX® brand, using its proprietary and innovative delivery technology which it expects to sell in Australia following any favourable decision.

The cannaQIX® range is manufactured under Good Manufacturing Practice standards and provides consumers with a standardised formulation and precise dosage measurement.


View Our Investment Portfolios


S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Australian ASX Small Cap stocks | Why Finfeed.com is Australia’s leading small cap publication

Founded seven years ago, Finfeed.com is Australia’s leading and longest standing website for investor and finance news, education and expert opinion.

Published by StocksDigital, Finfeed was created to report daily on the comings and goings of ASX listed stocks in the small cap market.

As the first digital publication dedicated specifically to this space, Finfeed soon became the most trusted publication in the market, quickly garnering over two million page views – a number that continues to rise.

Finfeed.com provides its readers with informative articles that tackle the latest in market moving #ASX small cap news, plus exclusive content you won’t find anywhere else. It is aimed at those with an interest in investing, market education, company performance, start-ups and much more.

Finfeed.com is the only media organisation operating under the strength of a Financial Services License and is backed by leading journalists and analysts all with brands of their own.

The website aims to inform, educate and entertain with content that drills down into the heart of financial matters.

Finfeed is a leading source of investor and market information, with everything investors need to know about how to invest written in a way that anyone can understand. 

Over the years, the website has expanded beyond exclusively reporting on small caps, to profile Australia’s leading ASX listed small, mid and large caps as well as some of the country’s most successful CEOs and business leaders to find out what makes them tick.

Every day you will find fresh content covering:

Fast Facts

Over 4,000 articles published

Over 2.3 Million Page Views and counting

Over 10,000 followers on social media

Subscriber list growing by 2% monthly

Thanks for subscribing!

X